Loading...
Bayer AG
BAYN.DE•XETRA
HealthcareDrug Manufacturers - General
€26.43
€0.005(0.02%)
Bayer AG (BAYN.DE) Financial Performance & Statements
Review Bayer AG’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns to understand its financial health and growth.
Revenue Growth
-2.16%
↓ 2.16%
Operating Income Growth
2318.00%
↑ 2318.00%
Net Income Growth
13.23%
↑ 13.23%
Operating Cash Flow Growth
43.99%
↑ 43.99%
Operating Margin
6.36%
↑ 6.36%
Gross Margin
53.99%
↑ 53.99%
Net Profit Margin
-6.98%
↓ 6.98%
ROE
-9.96%
↓ 9.96%
ROIC
3.65%
↑ 3.65%
Bayer AG (BAYN.DE) Financial Statements
Explore quarterly and annual reports including balance sheet, income statement, cash flow for Bayer AG stock.
| Metric | FY 2024 |
|---|---|
| Net Income | -$2.55B |
| Depreciation & Amortization | $8.78B |
| Deferred Income Tax | $0.00 |
| Stock Based Compensation | $0.00 |
| Change In Working Capital | $85.00M |
| Accounts Receivables | $197.00M |
| Inventory | $521.00M |
| Accounts Payables | $0.00 |
| Other Working Capital | -$633.00M |
| Other Non-Cash Items | $1.05B |
| Net Cash From Operating Activities | $7.37B |
| Investments In Property Plant & Equipment | -$2.78B |
| Acquisitions Net | -$167.00M |
| Purchases Of Investments | -$251.00M |
| Sales/Maturities Of Investments | $2.58B |
| Other Investing Activities | $784.00M |
| Net Cash Used For Investing Activities | $164.00M |
| Debt Repayment | -$5.02B |
| Common Stock Issued | $0.00 |
| Common Stock Repurchased | -$16.00M |
| Dividends Paid | -$131.00M |
| Other Financing Activities | -$2.01B |
| Net Cash From Financing Activities | -$7.18B |
| Effect Of Forex Changes On Cash | -$68.00M |
| Net Change In Cash | $284.00M |
| Cash At End Of Period | $6.19B |
| Cash At Beginning Of Period | $5.91B |
| Operating Cash Flow | $7.37B |
| Capital Expenditure | -$2.78B |
| Free Cash Flow | $4.59B |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan